Swiss National Bank Decreases Stake in Hologic, Inc. (NASDAQ:HOLX)

Swiss National Bank decreased its position in Hologic, Inc. (NASDAQ:HOLX) by 5.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 656,240 shares of the medical equipment provider’s stock after selling 36,500 shares during the period. Swiss National Bank owned 0.29% of Hologic worth $47,308,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HOLX. Swedbank AB increased its stake in Hologic by 18.8% in the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock valued at $157,788,000 after buying an additional 306,562 shares during the last quarter. GSA Capital Partners LLP boosted its holdings in Hologic by 22.2% in the 3rd quarter. GSA Capital Partners LLP now owns 5,762 shares of the medical equipment provider’s stock worth $469,000 after buying an additional 1,048 shares during the period. KBC Group NV boosted its holdings in Hologic by 2.1% in the 3rd quarter. KBC Group NV now owns 87,629 shares of the medical equipment provider’s stock worth $7,138,000 after buying an additional 1,820 shares during the period. Metis Global Partners LLC boosted its holdings in Hologic by 4.1% in the 3rd quarter. Metis Global Partners LLC now owns 15,655 shares of the medical equipment provider’s stock worth $1,275,000 after buying an additional 623 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. boosted its holdings in Hologic by 14.2% in the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 6,007 shares of the medical equipment provider’s stock worth $489,000 after buying an additional 748 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on HOLX. BNP Paribas raised shares of Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Jefferies Financial Group began coverage on shares of Hologic in a report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price target for the company. Evercore ISI cut their price target on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a report on Thursday, February 6th. Leerink Partnrs downgraded shares of Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Finally, Wolfe Research began coverage on shares of Hologic in a report on Friday, December 13th. They issued a “peer perform” rating for the company. Eleven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $84.62.

Hologic Stock Performance

Shares of NASDAQ:HOLX opened at $60.71 on Monday. The company has a market cap of $13.62 billion, a price-to-earnings ratio of 19.15, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a 50-day moving average price of $67.18 and a 200-day moving average price of $74.64. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 12 month low of $60.33 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, equities analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.